Table 3.
Multivariate analysis of the correlation between demographic and clinicopathological characteristics and survival time in patients with MM.
| Covariates | Overall survival | Progression-free survival | ||
|---|---|---|---|---|
| 95% CI for HR | P | 95% CI for HR | P | |
| Age | 1.005–1.038 | 0.011 | N/A | N/A |
| Ig isotype | N/A | N/A | 0.659–0.957 | 0.015 |
| ISS staging | 0.697–1.661 | 0.740 | 0.694–1.648 | 0.761 |
| Plt (×109/L) | 0.369–0.939 | 0.026 | 0.409–1.084 | 0.102 |
| Scr (μmol/L) | 0.977–2.453 | 0.063 | 0.975–2.501 | 0.063 |
| β 2-MG (μmol/L) | 0.665–2.524 | 0.447 | 0.849–3.244 | 0.138 |
| Ca (mmol/L) | 1.172–3.389 | 0.011 | 0.838–2.279 | 0.205 |
| Thalidomide | 0.277–0.612 | 0.000 | 0.286–0.641 | 0.000 |
| Blood transfusion | N/A | N/A | 0.735–1.453 | 0.849 |
ISS: International Staging System; Scr: serum creatinine; β2-MG: β2-microglobulin; Ca: calcium; HR: hazard ratio; CI: confidence interval; N/A: not available.